Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis

J Am Acad Dermatol. 2015 May;72(5):917-9. doi: 10.1016/j.jaad.2015.02.004. Epub 2015 Mar 5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase / blood*
  • Arthritis, Psoriatic / blood
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / drug therapy*
  • Blood Pressure / drug effects*
  • C-Reactive Protein / analysis*
  • Cohort Studies
  • Humans
  • Methotrexate / therapeutic use
  • Middle Aged
  • Psoriasis / blood
  • Psoriasis / drug therapy*
  • Retrospective Studies
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Alanine Transaminase
  • Methotrexate